Login to Your Account



Clinic Roundup


Wednesday, December 12, 2012
• Ligand Pharmaceuticals Inc., of San Diego, started a pivotal trial with Captisol-enabled, propylene glycol-free (PG-free) high-dose melphalan as a conditioning treatment prior to autologous transplant for patients with multiple myeloma.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription